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Abstract
Background: Communication between different health care providers (conventional and complementary) and
cancer patients about their use of complementary therapies affects the health and safety of the patients. The aim of
this study was to examine the qualitative research literature on the perception of and communication about the
risk of complementary therapies between different health care providers and cancer patients.
Methods: Systematic searches in six medical databases covering literature from 2000 to 2015 were performed. The
studies were accessed according to the level of evidence and summarized into different risk situations. Qualitative
content analysis was used to analyze the text data, and the codes were defined before and during the data
analysis.
Results: Twenty-nine papers were included in the primary analysis and five main themes were identified and
discussed. The main risk situations identified were 1. Differences in treatment concepts and philosophical values
among complementary and conventional health care providers. 2. Adverse effects from complementary products
and herbs due to their contamination/toxicity and interactions with conventional cancer treatment. 3. Health care
physicians and oncologists find it difficult to recommend many complementary modalities due to the lack of
scientific evidence for their effect. 4. Lack of knowledge and information about complementary and conventional
cancer treatments among different health care providers.
Conclusion: The risk of consuming herbs and products containing high level of toxins is a considerable threat to
patient safety (direct risk). At the same time, the lack of scientific evidence of effect for many complementary
therapies and differences in treatment philosophy among complementary and conventional health care providers
potentially hinder effective communication about these threats with mutual patients (indirect risk). As such, indirect
risk may pose an additional risk to patients who want to combine complementary therapies with conventional
treatment in cancer care. Health care providers who care for cancer patients should be aware of these risks.
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Background
Complementary therapies comprise a diverse set of
healing philosophies, therapies and products [1], that is
generally not taught in conventional medical schools [2].
The definition of complementary provider varies
between countries and organizations. We understand
complementary providers as “providers other than
authorized health personnel who give health-related
treatment outside the established health services.” This
definition is in line with the Norwegian law on alterna-
tive treatment [3]. For example, if an acupuncturist of-
fers acupuncture at a private clinic she or he is a
complementary provider. If a physiotherapist practices
acupuncture inside a hospital, the treatment is defined
as complementary treatment delivered as a part of her
or his appointment as a physiotherapist [4]. In Norway
and in the EU, the regulation of the complementary
profession varies widely [5]. This variation increases the
risk and thereby threatens patient safety. However, to
become a member of a complementary practitioner
organization, a minimum of training in conventional
medicine is usually required [6]. It is safe to assume that
complementary providers’ knowledge of conventional
medicine varies from no formal medical education to
being fully trained physicians who have added some
complementary modalities to their treatment repertoire.
According to the 2007 National Health Interview
Survey (NHIS), which included a comprehensive survey
on the use of complementary modalities by Americans,
65% of the respondents who had ever been diagnosed
with cancer had used complementary therapies [7]. The
prevalence of complementary therapy use is higher
among women, individuals with higher education, and
those with poorer self-reported health [8, 9].
Communication
Effective communication among health care providers is
essential to providing coordinate care [10]. Optimal com-
munication between health care providers is characterized
by the accurate gathering and sharing of information that
will be useful to other health care providers, indicating
what the patient has been told, planning who will take
ongoing responsibility for the patient and keeping the door
open for further communication [11, 12]. Effective com-
munication may also contribute to more confidence in
health care personnel by the patients and increased
likelihood that patients will follow evidence-based recom-
mendations and thereby avoidance of negative interactions
between conventional and complementary treatments [13].
The lack of effective communication between patients
and health care providers may result in loss of trust within
the therapeutic relationship [14]. Furthermore, patients
may select harmful, ineffective or expensive complemen-
tary modalities, when more effective and less expensive
complementary modalities may exist [14]. Communica-
tion in clinical encounters experienced by patients as
negative may also diminish patient autonomy and self-
efficacy and interfere with the self-healing response [15].
Patient-centered communication is the set of skills and
behaviors used by health care providers to promote a re-
lationship in which patients actively participate as part-
ners in healthcare decision making and management
[16]. A patient-centered relationship involves the concept
of mutuality, including power sharing and collaboration
between health care providers and patients. Another com-
monly described element is a “whole person” approach, in
which the provider attends not only to the patients’
biological needs, but also to the psychological, social and
behavioural dimension of health and illness [17]. A recent
Norwegian study among complementary users living with
cancer suggests that negative communication experiences
in consultations with conventional health care providers
may result in the decision to use complementary therapy
and even to delay or decline conventional cancer treat-
ment. On the contrary, positive communication experi-
ences lead to the decision to use complementary therapy
as a supplement rather than an alternative to conventional
medicine [18]. Effective patient-provider communication
may be essential in developing patient satisfaction, com-
pliance and positive health outcomes.
Users of complementary therapies report a signifi-
cantly “lower level of confidence in the efficacy of
conventional medicine” than non-users [19]. Neverthe-
less, most of these patients do not leave the conventional
health care system [20] although they may have negative
experiences with conventional care. It has been claimed
in studies on the quality of health care [21] that when
patients are treated with respect, given time to present
their health issues, being listened to and given the op-
portunity to actively participate in the decision-making,
they will stay with their general practitioner. A recent
Norwegian study revealed that the probability of visiting
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a complementary provider was lower (12.5 %) among
those with a general practitioner relationship lasting
more than 2 years compared to those with a shorter
relationship (15.5 %) [21].
Risk
Ideally, patients should be fully informed about the nature
of the specific complementary therapies, their potential
risks and benefits, and they should have realistic expecta-
tions when combining complementary and conventional
treatment in cancer care. However, possible risks associ-
ated with complementary therapies have been poorly in-
vestigated, often due to the assumption that many
complementary modalities are considered to be “natural”
and, therefore, associated with low risk. Risk associated
with any health care is generally separated into direct and
indirect risk [4, 22]. Direct risk is caused by the treatment
itself and is linked directly to the intervention. This
dimension includes traditional adverse effects from a
treatment, such as bleeding in response to acupuncture
needling, or the adverse effects of a herb, as well as risk
connected to health advice from the complementary
provider. Indirect risk is related to adverse effect of the
treatment context, e.g., the complementary provider,
rather than the intervention. A patient may be harmed by
a care context which prevents the patient from receiving
the best possible treatment relevant to her or his health
needs, e.g., when patients seek a complementary provider
for their health complaints which may be effectively
treated by conventional medicine (e.g., cancer), and the
complementary provider, often unwittingly, causes a delay
of conventional treatment [22, 23].
Studies have been conducted to map the communica-
tion gap between cancer patients and different health
care providers (conventional and complementary) in
cancer care [14, 24, 25] However, there is limited
research that captures the communication patterns
about risk of conventional and complementary health
care providers who care for cancer patients. To gain
knowledge about this important issue, a literature review
with the following aim was performed.
Aim
We will examine the qualitative research literature on
perception of and communication about the risk of com-
plementary therapies among oncology experts (doctors
and nurses), health care physicians and complementary
providers and cancer patients. The studies will be sum-
marized into different risk situations.
Methods
Searches
The focused question under investigation was:
How do health care providers (conventional and
complementary) perceive and communicate risk of
complementary therapies to patients who combine
conventional and complementary therapies in cancer
care?
The Population Exposure Outcome (PEO) format (tools
to formulate questions about qualitative research) was
used when searching for relevant articles, which
included the following three parts:
Population: Health care providers, oncology doctors,
nurses, physicians and complementary providers
Exposure: Risk-communication, risk-perception, risk
assessment regarding the use of complementary therap-
ies in cancer care
Outcome: Improved communication between different
health care providers, improved patient-provider com-
munication, enhance patient safety
The inclusion comprised qualitative studies (individual
and group interviews, opinion of an expert and literature
reviews) investigating communication and perception
about risk of complementary therapies among oncology
experts (doctors and nurses), health care physicians and
complementary providers and cancer patients. However,
qualitative studies that had added a quantitative compo-
nent e.g., a questionnaire in the design (mixed-design)
were also included in the analysis. The studies excluded
were quantitative studies and evidence based guidelines.
The following electronic databases were searched:
AMED, CINAHL, EMBASE, MEDLINE/PubMed and
PsycINFO.
Search methods
Depending on the database, various combinations of
medical subject headings (MeSH) terms and keywords
were used. The searches were combined with the Boolean
operators AND/OR. Titles, abstracts and keywords were
searched. These MeSH terms were used: complementary
therapies; cancer care unit; communication.
The following keywords were used: risk-perception;
risk-communication; interpersonal communication; deci-
sion making/and risk assessment; neoplasm; oncology;
cancer care; cancer center/cancer patient/patient care;
complementary and alternative medicine; alternative
treatment. The first author, T.S, performed the searches.
T.S, A.K and A.S read the articles and extracted the
data.
The findings of all relevant studies published in
English were synthesized. The searches were limited to
the period January 2000 to February 2015, due to the
shift in the acceptance of complementary therapies and
its inclusion in conventional health care in the past
10-15 years. Reference lists were hand searched, and
further searches of relevant authors were undertaken.
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(The PubMed search string is attached as Additional file
1 at the end of the manuscript.).
Methodological assessment of the included studies
The methodological quality of the included studies was
assessed using 10 questions from the Critical Appraisal
Skills Programme (CASP) checklist for qualitative re-
search www.casp-uk.net. This checklist is validated and
recommended by The Norwegian Knowledge Centre for
Health Services. First, three broad issues were consid-
ered: “Are the results valid?”, “What are the results?”
and “Will the results help locally?” Then two screening
questions were considered. If the answer to both was
“yes”, the studies were assessed according to eight
detailed questions (Table 1).
Design
We included qualitative studies in this review because
most of the so far limited knowledge on risk perception
and risk communication in clinical settings involving
cancer patients’ use of complementary therapies is based
on explorative, qualitative studies. A qualitative meth-
odological approach can give access to in-depth informa-
tion on the perspectives and practices of various
stakeholders involved in clinical settings. This includes
information on experiences from different interventions
applied in practice [26]. In general, qualitative studies
may contribute to deeper understanding and thorough
knowledge of different stakeholders’ perspectives on
health and well-being in terms of e.g., risk, communica-
tion and decision-making, especially in situations in
which we have limited previous knowledge of our
phenomenon of interest [27].
Data analysis
We used qualitative content analysis [28] to analyze the
results from the included studies. The goal was to
provide knowledge and understanding of the phenomena
of interest through a systematic classification process of
coding and identifying themes [29]. The codes were
identified before (“direct and indirect risk situations”)
and during the data analysis. Hence, the coding was a
mixed type, using elements from conventional and direct
content analysis [29]. From this analysis, concepts and
themes were developed. At each stage of the analysis
process, two researchers (AS and TS) met and discussed
after having read the relevant data several times and
made individual lists of coding suggestions. Data and
information obtained from the included studies will be
presented as results in this study. These results do not
represent the authors’ view or understanding of comple-
mentary therapies or conventional medicine.
Results
Searches
The literature search resulted in 350 potentially relevant
studies. All abstracts were screened for relevance. After
excluding 323 irrelevant studies (94 studies not including
complementary therapies, 127 studies not including com-
munication about complementary therapies, 56 studies
not including risk assessment of complementary therapies,
10 studies had a quantitative design and 36 studies com-
prised patient-provider communication), a total of 27
studies were included in this literature review (Fig. 1).
Twenty-seven studies [14, 23–25, 30–52] with a variety
of qualitative study designs, such as focus groups and indi-
vidual interviews, videotaped studies, literature reviews,
opinion of experts and mixed studies were included in this
review. Of these studies, 12 included complementary
providers [35–42, 48, 50–52], 5 included oncology experts
(doctors and nurses) [24, 25, 43, 44, 46] and 11 included
physicians [14, 23, 30–34, 45, 47, 49, 52].
Main themes
During the analysis, five main themes were revealed:
Risk perception (based on a risk-benefit comparison),
direct risk situations (adverse effects, interactions and
toxicity of a complementary intervention), indirect risk
situations (ethical risks, different models of disease caus-
ality and treatment philosophy, lack of regulation, stan-
dardized education and common medical terminology,
harms of treatment regimen), risk communication (inef-
fective patient-provider relationship, cancer patients who
delay or decline the use of conventional medicine, how
to talk about complementary use (factors that enhance
Table 1 10 questions for appraising qualitative research
(CASP checklist)
Screening Questions Responses
1. Was there a clear statement of the aims
of the research?
Yes Can’t tell No
2. Is a qualitative methodology appropriate? Yes Can’t tell No
Detailed questions
3. Was the research design appropriate to
address the aims of the research?
Yes Can’t tell No
4. Was the recruitment strategy appropriate
to the aims of the research?
Yes Can’t tell No
5. Was the data collected in a way that
addressed the research issue?
Yes Can’t tell No
6. Has the relationship between research and
participants been adequately considered?
Yes Can’t tell No
7. Have ethical issues been taken into
consideration?
Yes Can’t tell No
8. Was the data analysis sufficiently rigorous? Yes Cant’ tell No
9. Is there a clear statement of findings? Yes Cant’ tell No
10. How valuable is the research? Yes Cant ‘tell No
awww.casp-uk.net
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or obstruct communication), and information regarding
complementary therapies and conventional medicine
(lack of knowledge).
Risk perception based on a risk/benefit comparison
Seven papers addressed this theme [24, 25, 30–33]. The
theme was based on a risk/benefit comparison meaning
that the benefits have to clearly outweigh risks con-
nected to the use of a complementary modality for
health care providers to consider recommending it to
patients. The stronger the evidence for safety and effi-
cacy, the stronger the argument that the modality should
be recommended [24, 32]. However, health care physi-
cians and oncology experts find it difficult to recom-
mend a complementary modality because they doubt
that these modalities are beneficial due to limited scien-
tific evidence [14, 33]. The oncologists are particularly
critical of complementary therapies due to lack of scien-
tific evidence [24]. Moreover, physicians perceive com-
plementary therapies as a backup when conventional
medicine has little to offer for the patient. According to
these physicians, the reasons for offering complementary
therapies included being able to offer patients something
that would “do no harm” as an addition to pharmaco-
logical drugs that may have unpleasant adverse effects
[32]. It is, therefore, important to distinguish between
complementary modalities that give false hope of cure
and those that offer supportive care to improve the
patients‘sense of wellbeing [24, 25, 32].
Direct risk situations
Direct risks were identified as adverse effects, interactions
and toxicity of complementary therapies in this review.
We found that eight studies addressed this theme [24, 25,
30, 35–37, 49, 51]. Patients should be fully informed of
the nature of the specific complementary modalities, po-
tential risks and benefits, and realistic expectations. Com-
plementary products that may interact with conventional
cancer treatments, should not be used concurrently with
chemotherapy, as they lessen the effectiveness of the latter
[24, 25, 35]. However, it is possible to use other comple-
mentary products (that do not interact) concurrently with
anticancer drugs [35]. This information should be commu-
nicated to cancer patients so that they can take this into
consideration in their decision-making. The directive
2001/83/EC of the European Parliament and of the Coun-
cil of 6th November, 2001 on the Community code relating
to medicinal products for human use states that “no medi-
cinal product may be placed on the market of a member
state unless a marketing authorization has been issued by
the competent authorities of that member state in accord-
ance with this delivery or an authorization has been
granted in accordance with Regulation (EEC) No 2309/93”
[53]. Outside the EU many products are not undergoing
appropriate quality control, and precautions should be
taken in many cases. According to information obtained
from studies included in this review, Ayurvedic medicines
from India and herbs and products from the Middle East
may have high heavy metal content, and may contain bac-
teria and toxic organic substances [30, 37, 51].
Fig. 1 Flow chart of the inclusion process
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Indirect risk situations
Twenty-two studies addressed indirect risk situations
[14, 24, 25, 31–42, 44, 45, 47, 49–52]. Health care physi-
cians and oncology experts have an ethical responsibility
to initiate the communication regarding the use of com-
plementary therapies with cancer patients [45]. However,
according to data obtained from this literature review,
oncology doctors and physicians will discuss comple-
mentary therapies only when a patient him/herself raises
this issue within a consultation. This passive attitude
was linked to a lack of sufficient scientific evidence for
positive outcomes of complementary therapies found in
high quality randomized controlled trials (RCTs) [32].
Oncology nurses, on the other hand, sometimes actively
promote complementary modalities that they find to
correspond with their vision of holistic care [44].
According to the included studies, complementary
providers often differ from conventional health care
providers in their understanding of treatment concepts,
philosophies and diagnostic procedures. This leads to
different models of disease causality (cells, blood, nerves
vs. energy, vital force, meridians) and treatment philoso-
phy (reductionism vs. holism). As many complementary
providers are philosophically oriented towards personal
and spiritual growth, patients may feel guilty if the dis-
ease continues to advance despite the patients’ best spir-
itual and mental efforts [38]. According to Broom and
colleagues [24, 30], such philosophies may also give
patients false hope of recovery.
Another indirect risk connected to the combination
of conventional and complementary treatment in can-
cer care is the lack of regulation and standardized
education in many countries. Currently, there are, for
example, no standard training requirements for com-
plementary providers working in cancer care or any
other health care setting [42] in the EU [5]. Accord-
ing to Mackareth et al., complementary providers in
England need specific training to learn how to prac-
tice safely [54].
Moreover, there is a need for common medical ter-
minology to bridge the communication gap between
health care providers working outside the conven-
tional health care system [31, 37]. Common medical
terminology may reduce the existing communication
gap between conventional and complementary pro-
viders about mutual patients. To minimize communi-
cation gap between physicians, oncology experts and
complementary providers, a medical complementary
record should include a treatment plan with conven-
tional and complementary diagnosis, explanation of
terminology, possible treatment interactions, descrip-
tion of the complementary treatment plan and goals.
If possible, the quality of any complementary supple-
ment given should be reported [52].
Risk communication
A total of 18 studies addressed the theme of risk commu-
nication [14, 23–25, 30–33, 35–38, 43, 46–48, 51, 52].
Well-functioning communication has been associated
with trust in conventional health care and positive health
outcomes. An open and equal dialogue in clinical practice
may decrease risks associated with malpractice, maximize
positive treatment outcomes and avoid possible adverse
effects that may occur due to combinations of comple-
mentary and conventional cancer treatment [14]. How-
ever, research has revealed that oncology experts and their
patients often have significantly different perspectives on
the legitimacy of complementary therapies and the under-
standing of cancer in a broader sense [24]. According to
data obtained from this review, medical knowledge and
patients’ perceptions of risks and benefits associated with
complementary and conventional cancer care are incom-
patible when cancer patients choose to delay or decline
conventional treatment [23]. These patients challenge the
rationality of medical advice and the authority of the on-
cology experts. On the other hand, conventional health
care providers express that they want patients to actively
participate in the decision-making, but in line with their
own views of what constitutes an effective complementary
modality [32]. According to Ben-Arye and colleagues
cancer patients should be asked about their use of com-
plementary modalities. This will strengthen the patient-
doctor relationship [34] and patients favor complementary
providers who are regulated health professionals [42].
Contrariwise, complementary providers perceive them-
selves as gatekeepers for the patients. They mediate
between patients and physicians and serve as a bridge
between patients and their families and the oncology
experts. In this sense, complementary providers contribute
to improved patient-physicians dialogues [48].
To enhance communication with patients, it is better for
health care physicians to admit uncertainty regarding the
benefits and safety of a complementary modality. Address-
ing uncertainty may have a protective value by allowing
for space and hope [14]. However, as mentioned above,
many health care physicians will only discuss complemen-
tary therapies when a patient raises the issue in a consult-
ation because the scientific evidence for complementary
therapies is weak. Moreover, health care physicians
endorse complementary modalities that are the closest to
conventional medicine [32]. Oncology nurses, on the
other hand, are the patients’ advocate [24] and often medi-
ate between oncologists and patients [44].
Many oncologists perceive that time spent visiting
complementary providers is of little benefit for patients
who are in a palliative stage of cancer [35]. Moreover,
many oncologists are skeptical to many complementary
treatments because they are expensive, and patients
mostly have to pay for them out of pocket. In this sense,
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both financial costs and time loss are perceived as
communication barriers [25, 30, 35].
Information regarding complementary therapies and
conventional medicine
Nine papers addressed the theme “information regarding
complementary therapies and conventional medicine”
[24, 30–32, 42–44, 46, 50]. Lack of knowledge about
complementary therapies may represent a threat to well-
functioning communication. Data from this review
demonstrates that there is lack of knowledge regarding
the use of complementary therapies and complementary
products among oncologist experts (doctors and nurses)
and health care physicians. According to Kemper and
colleagues an Internet education program about safety
of complementary therapies and dietary supplements to
improve knowledge, confidence and communication
practice among health care providers in a health care
setting, reported significant and sustained improvements
in knowledge, confidence and communication practices
[55]. On the other hand, conventional health care
providers do not have to be experts in complementary
therapies to have a respectful, balanced and helpful
discussion about complementary therapy use with
patients [25].
A number of naturopathic medical schools in the US
are accredited by the US Department of Education, and
these providers have high levels of medical knowledge.
To treat patients, complementary providers must have
knowledge of the biomedical concepts of pathology [31].
However, due to lack of regulation and standardized
education in many countries, complementary providers
may lack adequate medical training. Research shows that
complementary providers want to be involved in cancer
care and are enthusiastic about a professional education
program [42, 50]. For example, they may have limited
knowledge regarding interactions of herbal supplements
and anticancer diets with conventional treatment,
showing a need to regulate complementary training and
professions [35] (Table 2).
Methodological assessment of the included studies
All studies reported a clear statement of the objectives
and described the study participants. The research design
comprised 11 semi-structured interviews, 2 descriptive
studies, 5 literature reviews, 2 Delphi processes, 1 focus
group interview, 2 methodological/theoretical papers, 1
opinion of an expert, 1 qualitative observational study
(video tape), 2 mixed method studies (survey and inter-
view (n = 1) and one study included both a Delphi process
and a survey (n = 1). The studies were methodologically
evaluated according to the CASP checklist. The majority
of the studies (n = 21) had valid results, and for six studies
(n = 6) the validity of the results could not be ascertained.
Four of these studies (n = 4) were literature reviews that
did not report the methodology of the literature searches
[14, 33, 34, 44]. One theoretical paper did not provide a
rationale for the references included [41] and one study
provided inadequate description of the credentialing
process [39]. Based on this evaluation we concluded that
the methodological quality of the majority of these studies
was generally high (see Table 2).
Discussion
A wealth of qualitative evidence was revealed in this sys-
tematic review of the literature. The qualitative evidence
was mainly based on individual interviews, focus group
interviews and literature reviews. Two-thirds of the
studies provided valid results, while one-third provided
less certain results, according to the CASP checklist. As
such, these studies represent the most comprehensive
set of risk perception and communication to date among
different health providers (conventional and comple-
mentary) involving patients’ use of complementary ther-
apies in cancer care.
Direct risk situations
Some complementary products may be contaminated or
contain high levels of toxins. This is an important risk
since consuming herbs with, for example, high doses of
mercury or lead, may be risky for patients [40, 56, 57].
Ayurvedic medicines, for example, are divided into 2
major types: herbal only and rasa shastra [57]. Rasa
shastra is an ancient practice of deliberately combining
herbs with metals, such as mercury, lead, iron and zinc, or
minerals, such as mica and gems (e.g., pearls). Rasa
Shastra practitioners claim that these medicines are safe
and therapeutic, if properly prepared and administered
(including processes of purification, to remove undesirable
qualities and enhance therapeutic power). However, in a
random sample of commercially prepared Ayurvedic med-
icines purchased on the Internet, nearly 21 % contained
detectable levels of lead, mercury or arsenic [57]. Thus,
daily dose limits of toxic metals and quality tests of these
products are warranted to enhance patient safety.
Indirect risk
Risk connected to clinical practice (indirect risk) was
another threat to patient safety. It is primarily the differ-
ence in disease causality and treatment philosophy that
seems to impede effective communication between
conventional and complementary providers. These
differences in epistemology and philosophical values
may also influence a feasible collaboration across profes-
sions negatively.
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Table 2 Description and methodological assessment of the included studies
Study ID Objectives Participants Setting Research design Methodological
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Table 2 Description and methodological assessment of the included studies (Continued)
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Moreover, the non-communication between conventional
and complementary health care providers is risky for
patients who have to integrate what they perceive to be
the best of conventional and complementary treatment
themselves. Negative experiences from doctor–patient
interaction and outcomes of conventional treatment can
influence the cancer patients’ decision to use complemen-
tary therapies, and to potentially decline or delay conven-
tional treatment [18]. Patients’ negative attitudes toward
conventional treatment have also been linked to possible
adverse effects of treatments [24, 58].
Risk perception
Conventional health care providers find it difficult to
recommend a complementary modality with low or no
scientific evidence of effect. The complementary
providers, on the other hand, claim that the methods
used to investigate effect (RCT research) are not suitable
for complementary therapies, since complementary
therapies treat the “whole person” and not a disease as
such [59]. However, researchers may investigate one
disease, but single agents are rarely applied as a treat-
ment intervention, which makes it difficult to apply RCT
designs. Studies of patients’ perspectives on benefits and
risks associated with the use of complementary therapies
have revealed that these patients experience other
benefits from complementary modalities, which may be
missed in some of the outcomes traditionally utilized in
RCT research [60, 61]. Moreover, cancer patients who
want to combine complementary and conventional treat-
ment differ from oncology experts in their perceptions
of risk associated with the use of both complementary
and conventional cancer treatment [23].
Discussions and analyses of issues regarding safety and
risk of complementary therapies primarily involve issues
of direct risk, usually including adverse effects and the
monitoring of these effects (e.g., surveillance). However,
direct risk forms only a part of the risk profile of any
medical treatment. Findings from this literature review
indicate that risk associated with clinical practice
(indirect risk) may pose an additional danger to patients.
This is in accordance with Wardle and Adams [62] who
claim that indirect risk in complementary therapy use is
generally similar to that associated with conventional
medical care. However, in the complementary field these
risks may be more severe due to lack of appropriate
regulation and legislation. In a study about complemen-
tary therapy regulations in Europe, Wiesener and col-
leagues [5] found that “what was defined and regulated
as complementary therapies in one country, could be
regulated either as conventional, complementary or
alternative medicine in other European countries, or not
regulated at all”. In some countries, for example, one
must be a medical doctor to practice homeopathy, but
in a neighboring country one may practice homeopathy
if registered as a “natural health practitioner”. These
researchers found that CAM in Europe is not regulated
according to any current theories dealing with risk and
patient safety. Consequently, CAM users, health
providers, researchers, and authorities have insufficient
information about the risk and safety situation, and
every stakeholder interprets the situation differently.
This situation in itself influences patient safety and risk
understanding [5, 63].
Methodological limitations
Strong efforts have been made to retrieve all studies on
the subject, but one cannot be absolutely certain that all
existing studies have been identified. However, a medical
librarian with extensive research expertise supervised the
first author when she performed the searches and
controlled the searches for bias. This methodological
approach may have minimized the possibility for
selection bias in this present review.
Practical implications
To provide safe and cooperative care, better cross educa-
tion is needed among health care providers with and
without complementary training. Complementary
providers should have a solid and updated education in
conventional medicine and their complementary-specific
modality, and conventional health providers should be
willing to seek a minimum of information regarding
complementary therapies. This step may improve the
current communication gap between different health care
providers and their patients. As mentioned, therapies out
of the spectrum of complementary therapies are generally
not licensed and are equally unregulated. Moreover, many
complementary modalities are derived from traditional
systems of medicine [64] with limited or no research trad-
ition. Therefore, there is little knowledge about efficacy,
effectiveness and biological mechanisms. Many products
are not subject to regulation, and some may be toxic.
These issues may also be key drivers in the communica-
tion challenges between different health providers.
Implication for further research
There is a lack of research that investigates how comple-
mentary providers communicate with their patients about
the risks of combining complementary and conventional
treatment in cancer care. Complementary providers’
attitudes towards conventional cancer treatment and how
these attitudes are communicated to cancer patients have
also not been adequately investigated. Research that
focuses on how complementary providers’ perceptions
about conventional cancer treatment influence patients’
treatment choices is needed as well.
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Conclusion
Direct risk such as the risk of consuming herbs and
products containing high level of toxins is a considerable
threat to patient safety. Indirect risks such as the lack of
scientific evidence of effect for many complementary
therapies and differences in treatment concepts and
philosophy may hinder effective communication be-
tween different health care providers in cancer care. As
such, indirect risk may pose an additional risk to cancer
patients who want to combine complementary therapies
with conventional treatment. Health care providers who
care for cancer patients should be aware of these risks.
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